Skip to Content

BNY Mellon International Equity C NIECX

Medalist Rating as of | See BNY Mellon Investment Hub
  • NAV / 1-Day Return 21.70  /  −0.32 %
  • Total Assets 283.5 Mil
  • Adj. Expense Ratio
    1.820%
  • Expense Ratio 1.820%
  • Distribution Fee Level Below Average
  • Share Class Type Level Load
  • Category Foreign Large Blend
  • Investment Style Large Growth
  • Min. Initial Investment 1,000
  • Status Closed
  • TTM Yield 0.91%
  • Turnover 46%

USD | NAV as of Jul 19, 2024 | 1-Day Return as of Jul 19, 2024, 10:17 PM GMT+0

Morningstar’s Analysis NIECX

Will NIECX outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

BNY Mellon International Equity C's Average Process Pillar and People Pillar ratings result in a Morningstar Medalist Rating of Neutral.

null Morningstar Manager Research

Morningstar Manager Research

Summary

Fees are a weakness here. The strategy's lofty fees are a high hurdle to clear, as it is priced within the most expensive quintile among peers.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings NIECX

  • Current Portfolio Date
  • Equity Holdings
  • Bond Holdings
  • Other Holdings
  • % Assets in Top 10 Holdings 30.6
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Novo Nordisk A/S Class B

3.88 11.8 Mil
Healthcare

Novartis AG Registered Shares

3.75 11.4 Mil
Healthcare

ASML Holding NV

3.68 11.2 Mil
Technology

Nestle SA

3.44 10.5 Mil
Consumer Defensive

Unilever PLC

2.87 8.8 Mil
Consumer Defensive

Lvmh Moet Hennessy Louis Vuitton SE

2.83 8.6 Mil
Consumer Cyclical

Siemens AG

2.68 8.2 Mil
Industrials

Sanofi SA

2.65 8.1 Mil
Healthcare

AstraZeneca PLC

2.48 7.6 Mil
Healthcare

Compagnie Financiere Richemont SA Class A

2.33 7.1 Mil
Consumer Cyclical